Hematology/Oncology Salary (2026): Why the Hospital, Not the Oncologist, Keeps the Chemotherapy Margin

What the 2026 Data Actually Shows

Hematology/oncology salary data varies more by practice setting than by almost any other variable — a pattern that will make sense once the buy-and-bill mechanism below is explained.

Based on 117 verified physician salary submissions on SalaryDr, updated May 18, 2026, the median hematology/oncology salary is $495,000 per year. The average is $534,854, translating to approximately $214 per hour based on a 48-hour work week. The 25th percentile is $440,000 and the 75th percentile is $550,000. Base salary averages $449,487 — 84 percent of total compensation. Top earners at the 90th percentile earn $1,440,000 or more annually. 91 percent receive bonus or incentive compensation.

Marit Health, drawing on 151 verified physician submissions as of May 21, 2026, shows a higher average of $578,815 and median of $540,000. The 25th percentile is $458,083 and the 75th percentile reaches $700,000, with the 90th percentile at $800,000.

The practice setting breakdown — the number that matters most in this specialty:

Hematologist/oncologists in medical groups earn $709,000 on average — significantly more than those in a hospital or health system, who average $559,000, according to Marit's data. That $150,000 gap between independent medical group practice and hospital employment is the largest practice-setting income differential of any specialty covered on this site, and it exists for a specific, mechanical reason explained below.

The FastRVU MGMA analysis shows a median of 7,200 wRVUs at approximately $55 per wRVU producing $395,000 in pure clinical wRVU-based compensation — the employed physician floor before any drug margin, infusion center ownership, or clinical trial revenue enters the picture.

The Mechanism: What "Buy-and-Bill" Actually Means

Every other specialty on this site generates income primarily from professional fees for services rendered — a wRVU-priced visit, procedure, or surgery. Oncology is structurally different. The drug itself is the largest line item in oncology practice revenue, and how that drug is purchased, marked up, and billed determines who profits from it.

How buy-and-bill works, step by step:

Step 1 — The practice purchases the drug. An oncology practice or hospital infusion center buys chemotherapy and biologic drugs directly from a wholesaler or specialty distributor — not the patient's insurance company, not Medicare, the practice itself. A single dose of a common biologic or immunotherapy agent can cost the practice $8,000 to $15,000 wholesale. A CAR-T cell therapy product can cost the practice $400,000 to $500,000 per patient.

Step 2 — The practice administers the drug to the patient. The physician and infusion nursing staff administer the drug via IV infusion, typically in a dedicated infusion suite. This generates a separate administration fee — billed using CPT codes like 96413 (chemotherapy infusion, first hour, 5.34 wRVUs) — which is the closest thing to a standard professional fee in this model.

Step 3 — The practice bills insurance for both the drug and the administration. The drug is billed using a J-code (a specific HCPCS billing code for injectable/infused drugs) at a rate tied to the drug's Average Sales Price (ASP) — typically ASP plus 6 percent under Medicare Part B for independent practices. The administration fee is billed separately using the E&M/infusion CPT codes.

Step 4 — The margin is the practice's profit. The difference between what the practice paid the wholesaler for the drug and what Medicare or commercial insurance reimburses at ASP+6% is the practice's drug margin. On a $10,000 drug acquired at a modest discount below ASP, the margin might be $300 to $800 per dose. On high-volume infusion centers treating dozens of patients per week across multiple cancer types, this margin — not the professional administration fee — has historically been the single largest revenue source in independent oncology practice.

Drug costs represent 60 to 80 percent of total oncology practice revenue, according to oncology revenue cycle management data — a proportion unlike any other specialty in medicine, where physician services typically drive the majority of revenue.

This is why buy-and-bill economics, not wRVU production, historically determined which oncology practices thrived. A practice with an efficient in-house infusion center, favorable wholesale drug pricing through group purchasing organizations, and high patient volume could generate meaningful margin on top of physician professional fees. A practice without in-house infusion — referring patients elsewhere for their chemotherapy — captured only the professional fee and left the drug margin on the table entirely.

The Mechanism That Destroyed the Model: 340B and Hospital Acquisition

Here is the part of oncology economics that almost no other physician finance resource explains at the depth practicing and prospective oncologists actually need.

What 340B is: The 340B Drug Pricing Program is a federal program that allows hospitals meeting specific eligibility criteria — primarily a disproportionate share of Medicaid and low-income patients — to purchase outpatient drugs at steeply discounted prices, often 25 to 50 percent below the drugs' list price. The program was designed in 1992 to help safety-net hospitals stretch scarce resources for underserved patients.

How the 340B margin works for hospitals: A 340B-eligible hospital buys the same chemotherapy or biologic drug that an independent oncology practice buys — but at the steep 340B discount. The hospital then bills Medicare and commercial insurance at the same ASP-based rate that an independent practice would bill. The difference between the deeply discounted 340B acquisition cost and the ASP-based reimbursement is dramatically larger than the margin an independent practice can generate buying at standard wholesale prices.

The average profit margin on oncology drugs purchased by hospitals through the 340B program reached 49 percent in 2015 — a margin that independent practices, purchasing at standard wholesale rates rather than the 340B discount, simply cannot match. 340B hospitals receive over one-third of all Medicare Part B oncology drug reimbursement nationally, despite representing a fraction of oncology providers.

This created a direct, powerful financial incentive for hospitals to acquire independent oncology practices. A hospital system that acquires a private oncology group converts every patient in that practice's infusion chairs into a 340B-eligible encounter — instantly capturing a drug margin that can be two to three times what the independent practice was generating on the same patient, the same drug, the same treatment. This is a form of vertical integration: over the past 15 years, there has been a significant shift in specialty drug administration from community physician practices to hospital outpatient facilities, driven primarily by health systems acquiring physician practices specifically to capture this margin differential.

The result, as of 2026: More than half — 58 percent — of all cancer specialists in America now practice within health systems rather than independent practices, according to research published in JCO Oncology Practice. This is one of the most dramatic consolidation shifts of any physician specialty in the modern healthcare economy, and 340B economics is the single largest driver.

What happens to the acquired oncologist's compensation: When an independent oncology practice is acquired by a hospital system, the acquired oncologists almost universally transition from a practice-owner compensation model — where they shared in professional fees, drug margin, and infusion center profits — to an employed, wRVU-based compensation model. The oncologist continues seeing the same patients, prescribing the same drugs, and administering the same infusions. But the drug margin that used to flow, in part, to the physician-owners now flows entirely to the hospital system. The oncologist is compensated for their wRVU production — the professional and administration fee component only — while the health system captures the (now 340B-discounted, ASP-reimbursed) drug spread that dwarfs the professional fee on many high-cost regimens.

This is the mechanical explanation for the data above: hospital-employed oncologists average $559,000 while independent medical group oncologists average $709,000. The clinical work is often identical. The difference is entirely about who captures the margin between drug acquisition cost and drug reimbursement.

The reimbursement policy fight that is actively reshaping this in 2026: CMS has proposed cuts to 340B drug payments for the 2027 outpatient payment rule, following a 2026 hospital acquisition-cost survey that found sizable differentials between 340B and non-340B drug costs. The policy direction — reducing the reimbursement spread hospitals receive on 340B drugs — is a direct response to years of advocacy from the Community Oncology Alliance, which has argued that Medicare overpayment for 340B drugs accelerates consolidation into higher-cost hospital settings and worsens what oncology economists call "financial toxicity" for patients. If these cuts proceed, the economic incentive that drove a decade and a half of oncology practice consolidation could meaningfully weaken — a policy development that any oncologist evaluating practice ownership versus hospital employment should track closely over the next several years.

Why This Matters for Your Practice Setting Decision

Understanding buy-and-bill and 340B economics is not academic — it is the single most important framework for evaluating any oncology job offer or practice ownership opportunity.

If you are evaluating a private practice or medical group position: Ask directly about the practice's infusion center ownership structure, drug purchasing arrangements (does the practice use a group purchasing organization for better wholesale pricing?), and — critically — how drug margin is distributed among physician-owners versus retained by the practice for overhead and growth. A practice with an efficient, high-volume, well-negotiated infusion center can produce the $600,000 to $709,000+ income levels the data shows for medical group oncologists. A practice without in-house infusion, referring chemotherapy administration elsewhere, forgoes this entirely and will compensate closer to the pure professional-fee wRVU model.

If you are evaluating a hospital-employed position: Understand explicitly that you will not participate in drug margin under almost any hospital employment structure. Your compensation will be built on wRVU production from E&M visits, chemotherapy administration codes, and procedural work (bone marrow biopsies, lumbar punctures for intrathecal chemotherapy). This is not necessarily a worse position — hospital employment offers stability, elimination of the significant business risk and capital investment that infusion center ownership requires, and access to institutional infrastructure (tumor boards, clinical trials, multidisciplinary care coordination) that independent practices increasingly struggle to match. But go in with clear eyes about the $150,000 average income gap this structural difference produces.

If you are evaluating a private-equity-backed oncology platform: PE acquisition of oncology clinics has grown substantially since 2003, and PE-backed platforms specifically pursue the buy-and-bill and infusion center economics that make oncology attractive to financial buyers. As documented in JCO Oncology Practice's analysis of PE in oncology, private equity is drawn to oncology precisely because of the drug margin dynamics described above — a PE platform that consolidates several independent oncology groups, negotiates better wholesale drug pricing through scale, and captures the resulting margin improvement is executing a financial strategy built directly on buy-and-bill economics. For the complete analysis of what a PE transaction means for a practicing physician, see our Private Equity Practice Acquisition guide.

Beyond Drug Margin: The wRVU Framework for Clinical Services

Drug margin is the specialty's defining economic feature, but professional fee wRVU production still matters — particularly for hospital-employed oncologists whose compensation is built entirely on it.

2026 CPT codes and wRVU values for core hematology/oncology services:

The wRVU benchmarks from MGMA (2026):

The important limitation of the wRVU model for oncology: Notice that the 90th percentile wRVU-based compensation of $522,500 sits well below the SalaryDr and Marit reported top-earner figures of $800,000 to $1,440,000+. This gap is the drug margin and infusion center ownership premium quantified directly — physicians at the true top of oncology compensation are not simply seeing more patients or documenting more thoroughly. They are capturing practice ownership economics that the wRVU model, by design, does not include.

For hospital-employed oncologists, the wRVU threshold and conversion factor negotiation matters enormously precisely because it is the only lever available — there is no facility fee or drug margin participation to negotiate around. Confirm your threshold is set at or below the MGMA 50th percentile (7,200 wRVUs) and your conversion rate is at or above $55 per wRVU. Use our Contract Analyzer to benchmark any offer.

Subspecialty and Career Path Income Comparison

The clinical trial revenue stream: Practices and academic centers with high clinical trial enrollment generate a genuinely separate revenue stream — typical additional income of $50,000 to $200,000 annually, with major trial sites generating $450,000 or more. This income comes from pharmaceutical sponsor payments for patient enrollment, data collection, and trial administration — entirely distinct from the buy-and-bill drug margin model. Academic oncologists, who otherwise earn the lowest base compensation in the specialty, partially close the gap with private practice through this trial revenue and through cutting-edge therapy access that attracts complex, well-insured referral patients.

Cellular therapy and transplant medicine — CAR-T cell therapy administration, bone marrow and stem cell transplant — represents the highest-complexity, highest-institutional-dependency subspecialty within hematology/oncology. These programs exist almost exclusively at large academic or specialized transplant centers given the infrastructure requirements (dedicated transplant units, apheresis capability, specialized nursing). Compensation reflects both the complexity premium and the institutional volume these centers command, typically reaching $500,000 to $700,000+ at established academic transplant programs.

Academic vs. Private Practice vs. Hospital-Employed: The Complete Picture

Academic hematology/oncology: $380,000 to $480,000

Academic oncologists at institutions like MD Anderson, Memorial Sloan Kettering, and Dana-Farber manage the most complex cancer cases in medicine, often as part of multidisciplinary tumor boards with access to the newest clinical trials and cellular therapies. The financial trade-off is real: often including protected research time, teaching responsibilities, and access to clinical trials — but at the lowest base compensation tier in the specialty. This is the tier where PSLF value matters most, covered below.

Hospital-employed oncology: $450,000 to $559,000

This is where the majority of American oncologists now practice — 58 percent of all cancer specialists, per the JCO Oncology Practice consolidation data. Salaries fall between $450,000 and $520,000 annually with productivity bonuses tied to wRVU targets and signing bonuses averaging $50,000 to $100,000. This tier offers meaningful stability and institutional infrastructure without the capital risk of infusion center ownership — a rational choice for many oncologists, particularly those early in their careers or those who prioritize clinical focus over the administrative and financial demands of practice ownership.

Private practice / medical group oncology: $600,000 to $800,000+, with top earners reaching $1,440,000

Private practice hematologist/oncologists earn the highest compensation, with potential for partnership equity, though physicians assume greater business risk and administrative responsibilities. This is the tier where buy-and-bill economics, when executed well through an efficient in-house infusion center and favorable drug purchasing, produces the compensation ceiling of the specialty. The trade-off is genuine: capital investment in infusion center infrastructure, exposure to drug pricing and reimbursement policy risk (including the 340B reform discussed above, which primarily affects hospitals but reshapes competitive dynamics for independent practices too), and the administrative burden of running an oncology practice's complex billing operation, where drug costs represent 60 to 80 percent of revenue and a single billing error on a high-cost immunotherapy claim can cost $20,000 to $50,000.

Geographic Variation and the Rural Shortage Premium

Rural and underserved areas typically offer 15 to 25 percent higher salaries than metropolitan markets to attract oncology specialists — a meaningful premium in a specialty where the training pipeline remains constrained relative to rising cancer diagnosis rates driven by an aging population.

After-tax geographic comparison:

The rural oncology shortage is particularly acute because cancer treatment requires infusion infrastructure that many rural hospitals cannot independently support — creating strong recruitment incentives, including loan repayment programs, for oncologists willing to serve these markets. For the complete after-tax analysis by state, see our Physician Salary After Taxes guide.

PSLF and Hematology/Oncology: Why Academic Employment Fits This Specialty Especially Well

Academic and hospital-employed oncology — the two lowest-compensated tiers of the specialty — are also disproportionately concentrated at nonprofit, PSLF-qualifying institutions. Major academic cancer centers (Dana-Farber, MD Anderson, Memorial Sloan Kettering, Mayo Clinic) and the majority of hospital systems that have acquired independent oncology practices through 340B-driven consolidation are 501(c)(3) nonprofit or public institutions. This makes PSLF an unusually good fit for a large share of practicing oncologists — precisely the physicians earning the lowest nominal compensation in the specialty.

A hematology/oncology fellow completing 3 years of internal medicine residency plus 3 years of fellowship accumulates 72 qualifying PSLF payments during training before their first attending paycheck. At a qualifying nonprofit employer, only 48 more payments — 4 years of attending service — are needed for complete forgiveness.

The dollar calculation:

Profile: Academic oncologist, $440,000 attending salary at a nonprofit academic cancer center, $295,000 in federal student loans, IBR enrolled from PGY-1.

• •Estimated IBR attending payment: approximately $2,850 per month
• •Remaining qualifying payments needed: 48 (given 72 accumulated during training)
• •Total attending-year PSLF payments: $2,850 × 48 = $136,800
• •Remaining loan balance forgiven tax-free: approximately $320,000 to $335,000
• •Refinancing alternative at 5.5% over 7 years: approximately $378,000 total paid

PSLF advantage: approximately $241,200 in total cost reduction, plus complete elimination of the remaining balance.

For an academic oncologist comparing a $440,000 academic position to a $650,000 private practice position, the $210,000 nominal gap is meaningfully offset by PSLF value over the first 4 attending years — narrowing the effective gap substantially while the physician builds subspecialty expertise and, in many cases, clinical trial access that would be harder to establish starting directly in private practice. Use our PSLF vs. Refinancing Calculator to model your specific numbers.

Career Stage: The Unusual Trajectory

Hematology/oncology shows a pattern that differs from most specialties on this site: early-career compensation is not meaningfully lower than mid-career compensation, and in some datasets it is actually higher.

Early career hematology/oncology physicians (0 to 5 years experience) earn a median salary of approximately $544,779, while those with 10 or more years of experience earn around $527,448 — a negative 3 percent change, per SalaryDr. Marit's data shows a similar pattern: compensation rises from $442,000 for those with 0 to 2 years to $594,500 for 6 to 10 years, then dips slightly to $581,500 for those with 11 or more years.

Why compensation plateaus or dips with seniority in this specialty: Starting salaries for hematologist/oncologists reached $490,000 in 2025, representing a 10-plus percent increase from the prior year — the training pipeline remains constrained relative to rising cancer incidence, and health systems are aggressively recruiting new graduates with strong signing bonuses to fill acute staffing gaps. Meanwhile, senior oncologists who reduce clinical volume, shift toward administrative or tumor board leadership roles, or move from high-volume infusion-heavy practice toward more cognitively focused consultative work see their wRVU-driven and drug-margin-driven compensation components decline correspondingly. This is a specialty where the newest graduates, recruited aggressively into acute-need markets, can out-earn oncologists a decade into practice who have deliberately reduced their infusion volume.

Residency and fellowship (6 years post-MD): $68,000 to $92,000 annually. Three years of internal medicine residency plus 3 years of combined hematology/oncology fellowship — among the longer non-surgical training pipelines in internal medicine, generating the substantial PSLF qualifying payment accumulation described above.

New attending, years 1 to 3: $440,000 to $600,000. Signing bonuses averaging $50,000 to $100,000 are standard, reflecting the acute national shortage relative to rising cancer diagnosis rates.

Lifestyle and Satisfaction: The Emotional Economics of Oncology

86 percent of hematologist/oncologists would choose their specialty again, per Marit Health data — a strong rate, though notably lower than the 93 to 95 percent rates seen in gastroenterology, urology, and ophthalmology elsewhere on this site. Satisfaction is 4.0 out of 5 on SalaryDr and 3.6 out of 5 on Marit — the lowest satisfaction scores of any specialty covered in this salary series.

Physicians cite the variety of cases and patient relationships as most rewarding aspects of this specialty. On-call demands, administrative burden, and work-life balance are cited as the top challenges. The lower satisfaction scores relative to other high-compensation specialties reflect a genuine and honest feature of this work: oncology involves a sustained emotional relationship with mortality that few other specialties confront as a routine, daily feature of practice. The longitudinal relationship an oncologist builds with a patient over years of treatment — through remission, recurrence, and in many cases, death — is clinically and emotionally distinct from the episodic, procedure-focused relationships that characterize most surgical specialties.

Palliative care dual-boarded oncologists may earn less on a per-hour basis but often report higher career sustainability and lower burnout — a data point worth taking seriously for oncology-bound residents evaluating the specialty's long-term emotional demands, not just its financial ones. For the complete analysis of how burnout intersects with physician financial planning, see our Physician Burnout and Finances guide.

The administrative burden specific to oncology: Because drug billing accuracy is so financially consequential — a single incorrect billing code or missing documentation on a high-cost immunotherapy claim can cost tens of thousands of dollars — oncologists and their practices carry a documentation and billing compliance burden that exceeds most other specialties. This administrative weight is a real and frequently cited driver of the lower satisfaction scores relative to the specialty's strong compensation.

Contract Terms for Hematologists/Oncologists: What to Negotiate

For private practice or medical group positions — the drug margin participation clause. This is the single most important negotiable term in oncology employment that has no equivalent in most other specialties. Understand explicitly: does the compensation formula include any participation in infusion center drug margin, or is your compensation entirely professional-fee/wRVU-based even within a private practice structure? Some medical groups pay associate physicians on a pure wRVU model for several years before partnership-track physicians gain access to drug margin distributions. Get the partnership timeline, the margin-sharing formula, and the buy-in requirements in writing before signing. See our Medical Practice Partnership Buy-In guide.

For hospital-employed positions — the wRVU threshold and conversion rate. Since drug margin participation is essentially never available in hospital employment, the wRVU threshold and conversion rate is the primary lever available. Confirm the threshold is set at or below the MGMA 50th percentile (7,200 wRVUs) and negotiate the highest defensible conversion rate, particularly if the hospital is capturing substantial 340B margin on your prescribing that you have no visibility into or participation in.

Clinical trial and research stipends. If clinical trial enrollment is part of your expected role, negotiate explicit compensation for trial-related administrative time and confirm whether enrollment-linked payments from sponsors flow to you, to a departmental research fund, or entirely to the institution.

Call coverage and cross-coverage structure. Oncology call — managing chemotherapy-related emergencies like febrile neutropenia, tumor lysis syndrome, and acute complications — carries real clinical weight even though it is less physically demanding than surgical trauma call. Specify call frequency, compensation, and whether call coverage is shared equitably across a group or disproportionately assigned to newer associates.

Malpractice tail provision. Oncology malpractice premiums run $15,000 to $30,000 annually — moderate relative to surgical specialties, reflecting the cognitive/medical rather than procedural nature of most oncology practice. Tail coverage at 200 to 250 percent of the annual premium remains a meaningful departure cost worth negotiating as employer-paid. See our Tail Coverage Explained guide.

Frequently Asked Questions